Next generation bone tissue engineering: non-viral miR-133a inhibition using collagen-nanohydroxyapatite scaffolds rapidly enhances osteogenesis.
Next generation bone tissue engineering: non-viral miR-133a inhibition using collagen-nanohydroxyapatite scaffolds rapidly enhances osteogenesis.
复制标题
DOI：
10.1038/srep27941
复制
发表时间：
2016-06-14
影响因子：
4.6
通讯作者：
O'Brien FJ
中科院分区：
文献类型：
--
作者：
Mencía Castaño I;Curtin CM;Duffy GP;O'Brien FJ
骨移植是全球第二大移植材料，每年给全球医疗系统造成的成本超过300亿美元。MicroRNAs对干细胞再生能力的影响为骨移植提供了巨大的治疗潜力；然而，它们有效地运送到靶点仍然是一个主要挑战。这项研究描述了带有miR-133a抑制复合体的多孔胶原纳米羟基磷灰石(NHA)支架的功能化，该支架使用非病毒nHA颗粒，通过对成骨的关键激活剂Runx2的新关注，增强了人类间充质干细胞介导的成骨。这项研究显示，Runx2和骨钙素的表达增加，碱性磷酸酶活性和钙沉积增加，从而证明了一种以前优化用于骨修复应用的生物材料的进一步增强的治疗潜力。该平台的前景看好的特点为骨修复和组织工程以外的众多应用提供了潜力，从而为基于microRNA的治疗提供了一个新的范例。
Bone grafts are the second most transplanted materials worldwide at a global cost to healthcare systems valued over $30 billion every year. The influence of microRNAs in the regenerative capacity of stem cells offers vast therapeutic potential towards bone grafting; however their efficient delivery to the target site remains a major challenge. This study describes how the functionalisation of porous collagen-nanohydroxyapatite (nHA) scaffolds with miR-133a inhibiting complexes, delivered using non-viral nHA particles, enhanced human mesenchymal stem cell-mediated osteogenesis through the novel focus on a key activator of osteogenesis, Runx2. This study showed enhanced Runx2 and osteocalcin expression, as well as increased alkaline phosphatase activity and calcium deposition, thus demonstrating a further enhanced therapeutic potential of a biomaterial previously optimised for bone repair applications. The promising features of this platform offer potential for a myriad of applications beyond bone repair and tissue engineering, thus presenting a new paradigm for microRNA-based therapeutics.